New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:48 EDTZGNXMedia coverage of Zogenix drug becoming more balanced, says Oppenheimer
Oppenheimer believes that the media's coverage of Zogenix's Zohydro is becoming less negative. The firm thinks that this change could ease headline pressure on the stock. Oppenheimer keeps a $5 price target and Outperform rating on the shares.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 13, 2015
09:11 EDTZGNXZogenix initiated with a Buy at Empire
Target $5.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use